

Tissue-specific expression of *NANOG* gene in human eye

Yuliya Markitantova^{Corresp., Equal first author, 1}, Yulia Smirnova^{Equal first author, 1}, Rina Zinovieva¹

¹ Koltzov Institute of Developmental Biology Russian Academy of Science, Moscow, RF, Russia

Corresponding Author: Yuliya Markitantova
Email address: yuliya.mark@gmail.com

The genes associated with multipotency in the eye cells at different stages of differentiation continue to be in the focus of biomedical research. In this study we revealed the changes in the *NANOG* mRNA expression in the human eye tissues at the early developmental stages. Using *in situ* hybridization we have obtained the new evidence for *NANOG* transcriptional activity in the human eye tissues at 8–10.5 weeks of prenatal development. *NANOG* transcriptional activity was detected in ectodermal derivatives tissues (cornea epithelium and lens) as well as in neuroectodermal tissue (neural retina). The highest *NANOG* mRNA concentration has been registered in cornea epithelium. The differences in the *NANOG* mRNA expression pattern could relate to the eye cells properties and their microenvironment. It is known that even in definitive tissue the epithelium retains the self-renew ability, while the retinal cells self-maintenance potential *in vivo* is extremely limited. Our findings confirm the presence of *NANOG* mRNA in tissues derived from different germ layers and clarifies the cellular markers characteristic of various eye cell types. The data obtained could help facilitate the understanding the cell biology and cell differentiation mechanisms.

1 Tissue-Specific Expression of *NANOG* Gene in Human Eye

2 Yuliya V. Markitantova¹, Yulia A. Smirnova¹, Rina D. Zinovieva¹

3 ¹ Koltzov Institute of Developmental Biology Russian Academy of Science, 26 Vavilova street,
4 Moscow, 119334, RF

5 *Corresponding author: Yuliya V. Markitantova. Email: yuliya.mark@gmail.com; Tel.:
6 +7(499)135-0052; Fax 7(499)135-8012

7 The authors contributed equally to this work.

8 Academic Editor: name

9 Received: date; Accepted: date; Published: date

10 **Abstract**

11 The genes associated with multipotency in the eye cells at different stages of differentiation continue to be
12 in the focus of biomedical research. In this study we revealed the changes in the *NANOG* mRNA
13 expression in the human eye tissues at the early developmental stages. Using *in situ* hybridization we
14 have obtained the new evidence for *NANOG* transcriptional activity in the human eye tissues at 8–10.5
15 weeks of prenatal development. *NANOG* transcriptional activity was detected in ectodermal derivatives
16 tissues (cornea epithelium and lens) as well as in neuroectodermal tissue (neural retina). The highest
17 *NANOG* mRNA concentration has been registered in cornea epithelium. The differences in the *NANOG*
18 mRNA expression pattern could relate to the eye cells properties and their microenvironment. It is known
19 that even in definitive tissue the epithelium retains the self-renew ability, while the retinal cells self-
20 maintenance potential *in vivo* is extremely limited. Our findings confirm the presence of *NANOG* mRNA
21 in tissues derived from different germ layers and clarifies the cellular markers characteristic of various
22 eye cell types. The data obtained could help facilitate the understanding the cell biology and cell
23 differentiation mechanisms.

24

25 **Keywords:** Human eye; development, differentiation; *in situ* hybridization

26 **Acknowledgments:** The work was conducted under the IDB RAS Government basic research program,
27 within the NIR topic № 0108-2018-0005; Russian Foundation for Basic Research, project no. 16-04-
28 01114. The research was performed using equipment of the Core Centrum of Institute of Developmental
29 Biology RAS. Authors thank Prof. Sukhikh G.T., PhD, Poltavzeva R.A., from the Research Center of
30 Obstetrics, Gynecology and Perinatology, Russian Academy of Medical Sciences, Moscow, for providing
31 the of post-operating eyes from different stages of human development for the study.

32 1. Introduction

33 In genetic regulation of mammal eye development the most intriguing question is the role of gene
34 associated with pluripotency. The transcription factors Oct4, Sox2, Klf4, c-Myc, Nanog and Lin28 have
35 previously been reported to form the core of a regulatory network controlling pluripotency of the
36 embryonic stem cells (ESCs). ESCs have unlimited capacity for self-renewal and an ability to
37 differentiate into more than 200 cell types (Boyer et al., 2005; Wang et al., 2006; Young, 2011). Stability
38 of *Oct4*, *Sox2*, *Nanog* expression is provided by autoregulatory loops resulting from the activation of their
39 intrinsic promoters, cross-activation of each other's promoters and by binding to the regulatory elements
40 of the specific genes sets (Kallas, Pook, Trei, & Maimets, 2014; Loh et al., 2006; Rodda et al., 2005).
41 Mechanisms regulating stemness are determined by cell properties, cell interactions and influence of the
42 numerous signaling pathways.(Mournetas, Sanderson, Fernig, Murray, & Nunes, 2014) Ectopic *Oct4*,
43 *Sox2*, *Klf4*, *c-Myc*, *Nanog*, *Lin28* genes expression is well-known to reprogramme the somatic cell
44 genome into embryonic state and alters the differentiation program (Hu, Friedrich, Johnson, & Clegg,
45 2010; Kim et al., 2009; Wernig et al., 2007). It has been established that the transcriptional factor Oct4
46 plays a key role in pluripotency induction and reprogramming (Pesce & Schöler, 2004). As have been
47 shown on eye models of various animals the functions of some of these regulators are not limited to the
48 pluripotency/multipotency (Camp et al., 2009; Pauklin, Thomasen, Pester, Steuhl, & Meller, 2011).

49 Analysis of the undifferentiated cells markers expression in differentiated cells during various periods of
50 vertebrate development is of great importance.

51 The subject of our interest is the multipotency genes expression, in particular the transcription factor
52 NANOG expression (www.ncbi.nlm.nih.gov; Gene ID: 79923, HGNC: 20857) in human eye ontogenesis.
53 NANOG contains a conservative DNA-binding homeo domain (Chambers et al., 2003; Hart, Hartley,
54 Ibrahim, & Robb, 2004) and has several pseudogenes (Booth & Holland, 2004). The gene is expressed at
55 highly level in the ESCs and testis, where the role of this gene in the cell's pluripotent status maintaining
56 have been proved (Hart et al., 2004; Hyslop et al., 2005; Mitsui et al., 2003). *NANOG* and *OCT4*
57 transcription activity significantly increases in tumor cells lines characterized by abnormal high
58 proliferation, in embryonic carcinoma and human retinoblastoma (Hart et al., 2005; Jeter, Yang, Wang,
59 Chao, & Tang, 2015; Seigel et al., 2007). A dual and sequential knockdown of *OCT4* and *NANOG* in
60 transformed human stem cells with features of cancer cells showed some functional divergence of
61 transcription machinery from the normal SC self-renewing state. Reduction in *NANOG* level expression
62 led to the loss of cancer stem cells (CSCs) self-renewal coupled with apoptosis (Ji, Werbowetski-Ogilvie,
63 Zhong, Hong, & Bhatia, 2009).

64 As for human eye the information about the multipotency markers in different cell types of definitive
65 tissues *in vivo* is poor and fragmentary. Expression of *NANOG* and other multipotency markers such as
66 *SOX2*, *OCT4*, *KLF4*, *NESTIN*, *PAX6* was revealed in the corneal limbus epithelial cells which retain the
67 ability of self-renewal in the adult eye (Pauklin et al., 2011). However, in the adult corneal epithelium the
68 level of *NANOG* transcriptional activity is extremely lower than in ESC. Earlier, the *NANOG* expression
69 was detected in the human eye at 10.5 week of prenatal development in non-dissected tissues of cornea,
70 total lens, retina, pigment epithelium with choroid, by PCR (Firsova et al., 2008). However, PCR can not
71 show the *NANOG* mRNA distribution in different eye cell types. In this study we focused on a detail
72 analysis of *NANOG* mRNA localization in the human eye tissues during the early prenatal development at
73 8–10.5 weeks of gestation.

74

75 2. Materials and Methods

76 2.1. Ocular tissues

77 The objects of the study were the eye tissues obtained from the human abortuses (post-operative
78 material) after legal abortions from medical terminations from licensed institutions of the Ministry of
79 Health of the Russian Federation, the Research Center of Obstetrics, Gynecology, and Perinatology,
80 Russian Academy of Medical Sciences, acting within the framework of the law of the Russian Federation
81 about protection of the health of citizens and according to the approved list of medical indications. The
82 age of fetuses was determined by an obstetrician. Foetal human eye tissues were obtained according to
83 ethics regard and appropriate measures to ensure biosafety, and accompanied with medical report on the
84 absence of pathologies. All manipulations on postoperative human material were performed in
85 accordance with European GTP (Good Tissue Practices) II Guidance (European Union Project in the
86 framework of the Public Health Program, 2003-2008) and Directive 2004/23/EC of The European
87 Parliament and of The Council of 31 March 2004 on setting standards of quality and safety for the
88 donation, procurement, testing, processing, preservation, storage and distribution of human tissues and
89 cells and approved by the Research Center of Obstetrics, Gynecology, and Perinatology, Russian
90 Academy of Medical Sciences; Ethics Committee of the Koltzov Institute of Developmental Biology
91 Russian Academy of Science (Ethical Application Ref: № 22, 15 March 20018). We have analysed the
92 eyes of 8 human embryos at 8–10.5 weeks of gestation (8, 9.5, 10, 10.5 week), two embryos for each
93 stage.

94 2.2. Histological analysis

95 The eyes of the embryos from 8 to 10.5 weeks of gestation were fixed in the Buen's solution, washed
96 in 70% ethanol, dehydrated in the series of alcohols of increasing concentrations and were embedded in
97 paraffin according to the method used earlier (Markitantova et al., 2008). Sections of 7 microns were
98 stained with hematoxylin followed by contrasting with eosin.

99 2.3 cDNA synthesis for RT-PCR and sequencing

100 Total RNA from the individual human retinas of 9.5 weeks was extracted by TRI Reagent (Sigma,
101 USA). To avoid contamination by genomic DNA the DNase digestion was performed (Fermentas, LTU).
102 The quantity and quality of the RNA were evaluated using NanoDrop system (Thermo Fisher Scientific,
103 USA) and gel electrophoresis. First-strand of cDNA was synthesized with 50 ng total RNA using
104 SuperScript RT (Gibco-BRL, USA) and random hexamer oligonucleotide primers (Sileks, RF).
105 Expression of well-known eye regulator *PAX6* was estimated as a control. Gene-specific primers for RT-
106 PCR were designed on the data of human genes structure from NCBI: *NANOG* (GenBank: AB093576.1),
107 *PAX6* (Gene ID: 5080) using Lasergene (DNASar software, USA). RT-PCR was performed using a
108 master kit (Sileks, RF). To exclude amplification from genomic DNA primers were synthesized from
109 flank intron/exon junctions and from different exons: for *NANOG*, 5'-CCTCCTCTTCCTCTATACTAA-
110 3' (from the boundary of the exon 1) and 5'-CTGCGTCACACCATTGCTATTTC-3' (from exon 4).
111 Primers for *PAX6* were: 5'-gtcatcaataaacagagtcttc-3' (exon 7); 5'-cgattagaaaaccatactgtat-3' (exon 10).
112 We had only one product 523 bp specific for *NANOG* and one product 424 bp specific for *PAX6*. The
113 cDNA was normalized by housekeeping gene *RPL19* (Gene ID: 6143). Primers for housekeeping *RPL19*
114 gene were: 5'-AGGGTACAGCCAATGCCCGA-3' (exon 4) and 5'-
115 CCTTGGATAAAGTCTTGATGATC-3' (exon 6), the fragment length was 326 bp. RT-PCR was
116 performed in thermocycler (Eppendorf, DE) according to the design. The reaction without cDNA
117 template was performed as the control for primers contamination. PCR products were visualized on 1.5%
118 agarose gel using DNA ladder 100 bp (Sileks M, RF). Gene's expression was estimated by a gel-analyzer
119 Quantity One (BioRad, USA). The identity of the amplified nucleotide sequences to the studied genes
120 was proved by sequencing on ABI PRIZM-3100 (Applied Biosystems, USA) system with BigDye 1.1
121 reagents (Thermo Fisher Scientific, USA) before cloning.

122 **2.4 PCR fragments Cloning and RNA probes synthesis for in situ hybridization**

123 The PCR fragments of *NANOG* (523 bp) and *PAX6* (424 bp) amplified on template of the human
124 retina of 9.5 week of gestation were cloned into the transcription vector using a TOPO TA cloning kit
125 (Invitrogen, USA). RNA probes were generated and labeled by *in vitro* transcription procedures. We

126 synthesized antisense RNA probes complementary to *NANOG* mRNA and *PAX6* mRNA and sense RNA
127 probes (negative controls) labeled with digoxigenin using Dig-labeling RNA kit (Roche, CHE).
128 Subsequent colorimetric reaction was performed using Dig RNA detection kit (Roche, CHE). The
129 efficiency of the probes labeled was assessed by direct hybridization signals detection on filters. The
130 probes concentration was 200 ng per 65 mkl hybridization buffer optimal for the clear hybridization
131 signal without the non-specific background staining. Corresponding sense probes used as negative
132 controls gave no hybridization signal.

133 ***2.5 Preparation of cryosections and in situ hybridization***

134 Human eyes at 8, 9.5, 10, 10.5 weeks of prenatal development were fixed in 4% paraformaldehyde
135 on the 0.1 M PBS (pH 7.4), at +4°C for cryosections. Six sections were stained for each eye in each
136 experiment. We didn't find out any significant biological variability. The eyes were washed in several
137 changes of 100 mM phosphate buffer (pH 7.5), incubated in 20% sucrose on 100 mM phosphate buffer, at
138 +4°C for 24 hours, embedded and frozen in TissueTec OCT (Leica, DE). Sections of 12 mm thickness
139 were prepared for *in situ* hybridization on a Leica CM1900 UV cryostat and were attached on Super frost-
140 Plus glass slides (Thermo Fisher Scientific, USA). Samples preparation and *in situ* hybridization
141 procedures were performed as described for the fish, and adapted for the human eye (Barthel & Raymond,
142 2004; Markitantova et al., 2008). The labeled antisense RNA probes were detected with an anti-
143 digoxigenin antibody that has been linked with the enzyme alkaline phosphatase (AP). After incubating
144 the antibody with the samples we detected the mRNA by adding the substrate BCIP (bromo-chloro-
145 indolyl-phosphate) and NBT (nitro blue tetrazolium). Slides were mounted in Immu-Mount (Thermo
146 Scientific™, USA) and then analyzed by microscopes Olympus DP70, DM RXA2 (Leica, DE). All the
147 experiments were repeated at least three times.

148

149 **3. Results**

150 We took into account the fact that *NANOG* gene has two highly homologous isoforms and 11
151 pseudogenes to design highly specific primers (Booth & Holland, 2004; Das, Jena, & Levasseur, 2011).

152 Human retina at the stage of 9.5 week served as a template for cDNA which was used for *NANOG* and
153 *PAX6* RNA probes synthesis for *in situ* hybridization (Figure 1).

154 We performed cDNA sequencing of PCR fragments completely overlapping the coding part of the
155 gene in order to avoid misinterpretation of the results of PCR analysis. The nucleotide sequence of human
156 *NANOG* gene (Gene ID: 79923) have been confirmed. PCR products of *NANOG* and *PAX6* were cloned
157 into the transcription vector pCRII-TOPO with dual promoters T7 and SP6 for DIG labeled-antisense and
158 sense riboprobes synthesis and were used for *NANOG* mRNA localization in the human eye during
159 8–10.5 weeks of development by *in situ* hybridization.

160 Histological analysis showed that at the stages studied the rudiments of all eye tissues had already
161 been represented in the germinative form except the ciliary body (Figure 2A). Cornea epithelium
162 differentiates into the outer layer consisting of flattened cells and the inner layer consisting of cuboidal
163 cells. In the retina, cells from the densely packed outer neuroblastic layer (ONbL) migrated to the newly
164 formed and more loosely packed inner neuroblastic layer (INbL).

165 We have found for the first time the *NANOG* transcripts localization in the eye tissues of ectodermal
166 origin (cornea and conjunctive epithelium, lens epithelium) and in the tissues of neuroectodermal origin,
167 retinal neuroblast layers in human fetuses of 8–10.5 weeks of development. *NANOG* was not detected in
168 the mesenchymal eye tissues.

169 According to our data the pattern of *NANOG* mRNA expression in the retina during these stages of
170 the eye development undergoes a change. The *NANOG* transcripts were localized predominantly in the
171 cells of the retina marginal area at 10.5 week of human gestation (Figure 2B,C). It was shown that cells
172 differentiation from this region of neural retina is delayed significantly relative to the central part.
173 Proliferating cells population of the retina marginal region was larger compared with the central area at all
174 time-points examined (Markitantova & Zinovieva, 2012) It has been shown that stem-like cells were
175 localized among the retina peripheral region cells which may be a potential source for retina restoration
176 (Bhatia, 2010). The distinct hybridization signal with *NANOG* mRNA was observed at the stage of 9.5-
177 10, 10.5 weeks in both inner and outer retina neuroblast layers (Figure 2B,C). The data about *NANOG*

178 mRNA distribution obtained by *in situ* hybridization in this study are consistent with the immunoassay
179 (Firsova et al., 2008).

180 In parallel we have studied the *PAX6* mRNA localization at the same eye developmental stages as a
181 positive control, because this transcription factor is well-known to be in control of the eye tissues
182 morphogenesis in vertebrates (Gehring, 1996; Nishina et al., 1999). The *PAX6* transcripts were revealed
183 in corneal as well as in lens epithelium of human eye at the all analyzed stages of gestation. We have
184 registered the most intensive hybridization signal to *PAX6* mRNA throughout the retinal neuroblasts at 8-
185 10.5 weeks and in the marginal area of the forming retina (Figure 3A,B). No hybridization signal was
186 observed in the mesenchymal eye cells (corneal endothelium, corneal and iris stroma) at all the studied
187 stages of the human eye development. Earlier *PAX6* protein was localized in the same eye tissues of
188 ectodermal (corneal and lens epithelium) and neuroectodermal (retina, ciliary body epithelium) origins,
189 but was not detected in mesenchymal tissues according to the data of fluorescent and non-fluorescent
190 immunochemistry (Firsova et al., 2009; Nishina et al., 1999). Functions of *Pax6* as a main regulator of the
191 multipotent cells proliferation in peripheral retina and of the exit of the retinal progenitor cells from the
192 cell cycle during differentiation of ganglion and amacrin cells in the mammal's eye have been proved
193 (Hsieh & Yang, 2009; Marquardt et al., 2001). Thus, our results on the analysis of the *NANOG* and *PAX6*
194 by *in situ* hybridization are in good agreement with the data obtained previously by others methods
195 (Firsova et al., 2009; Nishina et al., 1999) and confirm the transcriptional activity of the both genes in the
196 eye tissues studied. The transcription activity of the gene was also detected in the adult eye cells. Using
197 the reverse transcription PCR analysis, the minor amount of *NANOG* mRNA transcripts were also found
198 in the retina of the adult human (Firsova et al., 2008). Although, it is logical to assume that in mature cells
199 the level of gene expression can decrease and their role is not exclusively related to the cells
200 multipotency.

201 The *NANOG* in differentiated human eye cells can perform other function than maintenance of
202 pluripotency state. The previous reports demonstrated that *Oct4* and *Nanog* transcription must be silenced

203 when human ES cells differentiate, so that the developmentally important genes are activated. These
204 events during the early stages of embryogenesis are accompanied by accumulation of repressive
205 epigenetic marks such as DNA methylation, H3K9me3, and H3K27me3 while the neural genes *Pax6*, *N-*
206 *Oct3* acquired histone marks H3K4me3 associated with transcriptional activation (Das et al., 2011; Deb-
207 Rinker, Ly, Jezierski, Sikorska, & Walker, 2005).

208 4. Discussion

209 Recent researches of the multipotency genes have raised the question about their expression and
210 possibility to perform regulatory functions in the differentiating cells. The transcriptional factor
211 NANOG/Nanog has been considered only as a cell pluripotency marker for a long time. NANOG/Nanog
212 exhibited stage-specific activity in early mammalian embryogenesis similar to OCT4/Oct4 (Chambers et
213 al., 2003; Kallas et al., 2014; Pesce & Schöler, 2004). Blocking the expression of pluripotency factors in
214 early period of mammalian embryos development is considered to be a necessary step for realization of
215 the molecular programs of specific cell type differentiation (Liang et al., 2008). In light of recent studies
216 the range of Nanog functions is much wider (Camp et al., 2009; Hu et al., 2010; Jeter et al., 2015).

217 In the present study we first have obtained the data on the *NANOG* mRNA distribution in the human
218 eye tissues development at 8–10.5 weeks (Figure 2B,C) in comparison to *PAX6* mRNA (Figure 2D,E).
219 We have found the similar pattern of tissue-specific mRNA distribution for both regulatory genes in the
220 eye tissues. Our results on *NANOG* mRNA localization in the corneal epithelium during the early
221 embryogenesis confirm the data obtained in the adult human eye by other authors (Pauklin et al., 2011).
222 The *Nanog* expression level increases in the epithelium cells of esophagus, oral cavity, skin (Piazzolla et
223 al., 2014), that led to the suggestion about high selective activity *Nanog* in self-renewal epithelial tissues.
224 Functions of *NANOG* gene during the early eye development are not clear yet they may be related to the
225 regulation of the proliferative activity of eye progenitor cells.

226 However, we have determined the *NANOG* mRNA localization not only in forming human
227 cornea, but also in the neural retina. Previously, the high expression levels of other cells multipotency
228 regulatory gene-marker *GNL3* and *Ki67* (cell cycle marker) in proliferating retinal neuroblasts had been

229 determined at 9–11 weeks (Markitantova & Zinovieva, 2012). *GNL3* controls the proliferative activity
230 and cells multipotent state in ESC, neural SC and some cancer cell lines (Ma & Pederson, 2008; Nomura
231 et al., 2009). In general, there is a similarity in the expression pattern of regulatory genes *NANOG*, *PAX6*,
232 *GNL3* and *Ki67* in the analyzed human eye tissues at the early stages of development. The functional
233 relationship of *Nanog* and the cell cycle machinery in mammal embryogenesis have been established: the
234 high level of *Nanog/NANOG* expression in mouse and human ESCs is necessary not only to maintain
235 undifferentiated cell status (Chang, Wang, Knott, Chen, & Cibelli, 2009), but to trigger the G1-S
236 transition in the cell cycle as well (Zhang et al., 2009). *Nanog* is able to suppress directly the p27^{KIP1}
237 expression after transduction of mouse fibroblasts in somatic cells as was shown by high-resolution
238 massive DNA sequencing of chromatin immunoprecipitation (ChIP-seq) (Münst et al., 2016). It is well-
239 known that the continuous ESCs cell cycle is provided by the coordinated operation of signaling
240 pathways STAT3, LIF, PI3 kinase pathway, WNT, TGF, BMP, FGF and others (Kemp, Willems, Abdo,
241 Lambiv, & Leyns, 2005; Li et al., 2004; Loh et al., 2006). The same signaling molecules are involved in
242 the control of specific cell differentiation that can be maintained through alternative molecular
243 components. The increase in the *NANOG* expression level in tumor stem cells and certain types of cancer
244 cells is also accompanied by reactivation of molecular mechanisms leading to cell proliferation increasing
245 (Jeter et al., 2015). *Nanog* overexpression synergizes with gene *AURKA*, critical mitosis marker, to induce
246 proliferation, neoplastic growth, chromosomal aberrations (Jeter et al., 2015). RNA interference-mediated
247 silencing of *NANOG* reduced cells proliferative activity and *CyclinD1* expression in the same chain by
248 ChIP data (Han et al., 2012). *NANOG* increases the cell proliferation in liver cancer through the
249 Nodal/Smad3 pathway (Sun et al., 2013). We have found the transcriptional activity of the gene *NANOG*
250 in somatic differentiating cells of the eye tissues of various origins in human ontogenesis (Firsova et al.,
251 2008). Wide pattern localization of *NANOG* mRNA in the eye tissues suggests its multifunctional role in
252 special cellular and molecular niches. The eye tissues at the studied stages are still developing and mostly
253 undifferentiated. The current evidence in the field, together with *NANOG*'s mRNA pattern similar to that
254 of *Pax6* as we have indicated, would rather support the hypothesis that *NANOG* and *PAX6* transcripts are

255 present in proliferating progenitors in the developing ocular tissues and that it is then down-regulated as
256 the cells exit the cell cycle and commit to differentiating into specific cell types.

257 It should be noticed that each cell type is characterized by a certain epigenetic status of the genome
258 that programs gene expression (Melcer et al., 2012). The analysis of the ESC and tumor stem cells shows
259 that regardless of their origin the promoters of *Nanog* and *Oct4* are hypomethylated, and a high level of
260 expression of these genes is observed. In somatic cells, trophoblast stem cells and NIH/3T3 cells (mouse
261 embryonic fibroblast cells) *Nanog* promoter is hypermethylated, and transcription is repressed (Hattori et
262 al., 2007). However, histone modification, DNA methylation and acetylation are only some aspects of the
263 epigenetic mechanisms regulating the genes transcription through a complicated step-by-step process.
264 Recent findings have demonstrated the role of endogenous non-coding RNA molecules, including long
265 noncoding RNAs (lncRNAs) in the cell choice to self-renewal or differentiation into any lineage. In
266 mouse embryonic stem cells the specific sets of the lncRNAs modulate developmental state: knockdown
267 and overexpression of these transcripts lead to the substantial changes in *Oct4* and *Nanog* mRNA levels
268 and to the shifts in cellular lineage-specific gene expression and in pluripotency mouse ESCs (Mohamed,
269 Gaughwin, Lim, Robson, & Lipovich, 2010). At least 20 lncRNA inducing the expression of *Nanog* and
270 *Oct4* are known (Ghosal, Das, & Chakrabarti, 2013). In addition to non-coding RNAs, the highly
271 homologous isoforms and pseudogenes may contribute to differential regulation and tissue-specific
272 *NANOG* and *OCT4* expression (Das et al., 2011; Lin, Shabbir, Molnar, & Lee, 2007; Pain, Chirn,
273 Strassel, & Kemp, 2005). For example, cell type-specific *NANOG* and its pseudogene *NANOGP8*
274 expression were revealed in both undifferentiated and differentiated human cells. It is supposed that
275 rapidly dividing cells such as neonatal fibroblasts, cell line human epitheloid cervix carcinoma (HeLa),
276 cell line human neuroblast from neural tissue (SH-SY5Y), human mesenchymal stem cells (MSCs),
277 human ESCs express *NANOG* while relatively slow dividing cells such as adult fibroblasts, heart tissue,
278 human umbilical vein endothelial cells (HUVECs) have both *NANOG* and *NANOGP8* (Ambady et al.,
279 2011). In terminally differentiated smooth muscle cells known as the slowest cycling cells only

280 NANOGP8 is expressed. Nevertheless, it was reported that all the analyzed cell types were potentially
281 capable of binding a NANOG consensus sequence *in vitro* system (Ambady et al., 2011).

282 Despite of considerable interest to epigenetic regulation the data for the human eye tissues are
283 fragmentary, contradictory, dealing with a limited number of regulatory genes (Bonnin, Belville,
284 Chiambaretta, Sapin, & Blanchon, 2014; Qu et al., 2010; Rai et al., 2006). Eye cells differentiation is not
285 only accompanied by specific changes in the DNA, histones modification, but also non-coding RNAs
286 expression, nucleolar reorganization. The main aspects of epigenetic regulation in the eye are summarized
287 in detail in review (Cvekl & Mitton, 2010). Unfortunately, there are no comprehensive data on regulation
288 of the multipotency genes in the human eye in this regard.

289 Data obtained showed that *NANOG* expressed selectively in both ectodermal and neuroectodermal
290 human eye tissues in embryogenesis. The expression of *NANOG* in human eye in development may be
291 related to the cells proliferation and differentiation and can be explained by the cells type peculiarities:
292 cell cycle kinetics, the differentiation state in specific cellular and molecular niche that undergoes
293 dynamics in ontogenesis.

294 **5. Conclusions**

295 The results obtained extend the dataset currently available for the developing human retina (Tian
296 et al., 2015; Hoshino et al., 2017; Mellough et al., 2019) and open up the new prospects for future
297 investigation of the transcriptional factor NANOG role in genetic regulation of human eye tissues
298 differentiation. Data on *NANOG* expression in the eye tissues of different embryonic origins contribute to
299 the clarification of genetic processes in the human eye cells and may be taken into account for the
300 development of differential cell and tissue therapy methods. Such approaches are being developed for
301 other system to differential cancer therapy based on selective regulation *Nanog*, *Oct-4*, *Sox2*, *Klf4*
302 expression in P19 embryonic carcinoma stem cells through transcriptional factor decoys (TFDs) thus
303 downregulating the genes expression in a specific manner (Rad et al., 2015). Knowledge of the
304 multipotency genes expression specificity and their role in regulatory networks in the human eye tissues

305 is a prerequisite for the successful application of biotechnological approaches to solve a number of
306 problems associated with the eye pathologies.

307 **Conflicts of Interest:** The authors report no conflicts of interest.

308 References

- 309 1. Ambady S, Malcuit C, Kashpur O, Kole D, Holmes WF, Hedblom E, Page RL, Dominko T. 2007.
310 Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human
311 cells. *International Journal of Developmental Biology* 54:1743–54
- 312 2. Barthel LK, Raymond PA. 2000. In situ hybridization studies of retinal neurons. *Methods in*
313 *Enzymology* 316:579–90
- 314 3. Bhatia B, Singhal S, Jayaram H, Khaw PT, Limb GA. 2010. Adult retinal stem cells revisited *Open*
315 *Ophthalmology Journal* 4:30–38
- 316 4. Bonnin N, Belville C, Chiambaretta F, Sapin V, Blanchon L. 2014. DNA methyl transferases are
317 differentially expressed in the human anterior eye segment. *Acta Ophthalmologica* 92:e366–e371
- 318 5. Booth HA, Holland PW. 2004. Eleven daughters of Nanog. *Genomics* 84:229–38
- 319 6. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar
320 RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA. 2005. Core
321 transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 122:947–56
- 322 7. Camp E, Sanchez-Sanchez AV, Garcia-Espan A, Desalle R, Odqvist L, O'Connor JE, Mullor JL.
323 2009. Nanog regulates proliferation during early fish development. *Stem Cells* 27:2081–91
- 324 8. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. 2003. Functional
325 expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* 113:643–
326 55
- 327 9. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, Orlov YL, Zhang W, Jiang J, Loh
328 YH, Yeo HC, Yeo ZX, Narang V, Govindarajan KR, Leong B, Shahab A, Ruan Y, Bourque G, Sung
329 WK, Clarke ND, Wei CL, Ng HH. 2008. Integration of external signaling pathways with the core
330 transcriptional network in embryonic stem cells. *Cell* 133:1106–17
- 331 10. Cvekl A, Mitton KP. 2010. Epigenetic regulatory mechanisms in vertebrate eye development and
332 disease. *Heredity (Edinburgh)* 105:135–51
- 333 11. Das S, Jena S, Levasseur DN. 2011. Alternative splicing produces Nanog protein variants with
334 different capacities for self-renewal and pluripotency in embryonic stem cells. *Journal of Biological*
335 *Chemistry* 286:42690–703

- 336 12. Deb-Rinker P, Ly D, Jezierski A, Sikorska M, Walker PR. 2005. Sequential DNA methylation of the
337 Nanog and Oct-4 upstream regions in human NT2 cells during neuronal differentiation. *Journal of*
338 *Biological Chemistry* 280:6257–60
- 339 13. Firsova NV, Markintantova YV, Smirnova YA, Panova IG, Sukhikh GT, Zinov'eva RD, Mitashov
340 VI. 2008. Identification of the OCT4-pg1 retrogene and NANOG gene expression in the human
341 embryonic eye. *Biology Bulletin* 35:108–12
- 342 14. Firsova NV, Markitantova YuV, Smirnova Yu.A, Panova IG, Sukhikh GT, Zinovieva RD. 2009.
343 Temporal and spatial distribution of PAX6 gene expression in the developing human eye.
344 *Doklady Biological Sciences* 426:264–66
- 345 15. Gehring WJ. 1996. The master control gene for morphogenesis and evolution of the eye. *Genes Cells*
346 1:11–15
- 347 16. Ghosal S, Das S, Chakrabarti J. 2013. Long noncoding RNAs: new players in the molecular
348 mechanism for maintenance and differentiation of pluripotent stem cells. *Stem Cells and Development*
349 22:2240–53
- 350 17. Han J, Zhang F, Yu M, Zhao P.Ji.W, Zhang H, Wu B, Wang Y, Niu R. 2012. RNA interference-
351 mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast
352 cancer cells. *Cancer Letters* 321:80–88
- 353 18. Hart AH, Hartley L, Ibrahim M, Robb L. 2004. Identification, cloning and expression analysis of the
354 pluripotency promoting Nanog genes in mouse and human. *Developmental Dynamics* 230:187–98
- 355 19. Hart AH, Hartley L, Parker K, Ibrahim M, Looijenga LH, Pauchnik M, Chow CW, Robb L. 2005.
356 The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. *Cancer*
357 104:2092–98
- 358 20. Hattori N, Imao Y, Nishino K, Ohgane J, Yagi S, Tanaka S, Shiota K. 2007. Epigenetic regulation of
359 Nanog gene in embryonic stem and trophoblast stem cells. *Genes to Cells* 12:387–96
- 360 21. Hoshino A, Ratnapriya R, Brooks MJ, Chaitankar V, Wilken MS, Zhang C, Starostik MR, Gieser L,
361 La Torre A, Nishio M, Bates O, Walton A, Bermingham-McDonogh O, Glass IA, Wong ROL,
362 Swaroop A, Reh TA. 2017. Molecular Anatomy of the Developing Human Retina. *Dev Cell* Dec
363 18:43(6):763-779.e4. doi: 10.1016/j.devcel.2017.10.029. Epub 2017 Dec 7.
- 364 22. Hsieh YW, Yang XJ. 2009. Dynamic Pax6 expression during the neurogenic cell cycle influences
365 proliferation and cell fate choices of retinal progenitors. *Neural Development* 4:1–19
- 366 23. Hu Q, Friedrich AM, Johnson LV, Clegg DO. 2010. Memory in induced pluripotent stem cells:
367 reprogrammed human retinal-pigmented epithelial cells show tendency for spontaneous re-
368 differentiation. *Stem Cells* 28:1981–91

- 369 24. Hyslop L, Stojkovic M, Armstrong L, Walter T, Stojkovic P, Przyborski S, Herbert M, Murdoch
370 A, Strachan T, Lako M. 2015. Downregulation of NANOG induces differentiation of human
371 embryonic stem cells to extraembryonic lineages. *Stem Cells* 23:1035–43
- 372 25. Jeter CR, Yang T, Wang J, Chao HP, Tang DG. 2015. NANOG in cancer stem cells and tumor
373 development: an update and outstanding questions. *Stem Cells* 33:2381–90
- 374 26. Ji J, Werbowetski-Ogilvie TE, Zhong B, Hong S-H, Bhatia M. 2009. Pluripotent transcription
375 factors possess distinct roles in normal versus transformed human stem cells. *PLoS ONE* 4:e8065:1–9
- 376 27. Kallas A, Pook M, Trei A, Maimets T. 2014. SOX2 is regulated differently from NANOG and OCT4
377 in human embryonic stem cells during early differentiation initiated with sodium butyrate. *Stem Cells*
378 *International* 1–13
- 379 28. Kemp C, Willems E, Abdo S., Lambiv L, Leyns L. 2005. Expression of all Wnt genes and their
380 secreted antagonists during mouse blastocyst and postimplantation development. *Developmental*
381 *Dynamics* 233:1064–75
- 382 29. Kim JB, Sebastiano V, Wu G, Araúzo-Bravo MJ, Sasse P, Gentile L, Ko K, Ruau D, Ehrich M, van
383 den Boom D, Meyer J, Hübner K, Bernemann C, Ortmeier C, Zenke M, Fleischmann BK, Zaehres
384 H, Schöler HR. 2009. Oct4-induced pluripotency in adult neural stem cells. *Cell* 136:411–19
- 385 30. Liang J, Wan Ma, Zhang Yi, Gu P, Xin H, Jung SY, Qin J, Wong J, Cooney A, Liu D, Songyang Z.
386 2008. Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem
387 cells. *Nature Cell Biology* 10:731–39
- 388 31. Lin H, Shabbir A, Molnar M, Lee T. 2007. Stem cell regulatory function mediated by expression of a
389 novel mouse Oct4 pseudogene. *Biochemical and Biophysical Research Communications* 355:111–16
- 390 32. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen Xi, Bourque G, George J, Leong B, Liu J,
391 Wong KY, Sung KW, Lee CW, Zhao XD, Chiu KP, Lipovich L, Kuznetsov VA, Robson P, Stanton
392 LW, Wei CL, Ruan Y, Lim B, Ng HH. 2006. The Oct4 and Nanog transcription network regulates
393 pluripotency in mouse embryonic stem cells. *Nature Genetics* 38:431–40
- 394 33. Ma H, Pederson T. 2008. Nucleostemin: a multiplex regulator of cell-cycle progression. *Trends in*
395 *Cell Biology* 18:575–79
- 396 34. Markitantova YV, Firsova NV, Smirnova YA, Panova IG, Sukhikh GT, Zinovieva RD, Mitashov VI.
397 2008. Localization of the PITX2 gene expression in human eye cells in the course of prenatal
398 development. *Biology Bulletin* 35:113–20
- 399 35. Markitantova YuV, Zinovieva RD. 2012. Expression of nucleostemin in proliferating and
400 differentiating cells of the human retina during prenatal development. *Doklady Biological Sciences*
401 445:244–46

- 402 36. Marquardt T, Ashery-Padan R, Andrejewski N, Scardigli R, Guillemot F, Gruss P. 2001. Pax6 is
403 required for the multipotent state of retinal progenitor cells. *Cell* 105:43–55
- 404 37. Melcer S, Hezroni H, Rand E, Nissim-Rafinia M., Skoultchi A, Stewart CL, Bustin M, Meshorer E.
405 2012. Histone modifications and lamin A regulate chromatin protein dynamics in early embryonic
406 stem cell differentiation. *Nature Communications* 19:1–12
- 407 38. Mellough CB., Bauer R, Collin J, Dorgau B, Zerti D, Dolan DWP., Jones CM., Izuogu OG., Yu M,
408 Hallam D, Steyn JS, White K, Steel DH, Santibanez-Koref M, Elliott DJ, Jackson MS., Lindsay S,
409 Grellscheid S and Lako M. 2019. An integrated transcriptional analysis of the developing human
410 retina. *Development* 146. dev169474. doi:10.1242/dev.169474
- 411 39. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M,
412 Yamanaka S. 2003. The homeoprotein Nanog is required for maintenance of pluripotency in mouse
413 epiblast and ES cells. *Cell* 113:631–42
- 414 40. Mournetas V, Nunes QM, Murray PA, Sanderson CM, Fernig DG. 2014. Network based meta-
415 analysis prediction of microenvironmental relays involved in stemness of human embryonic stem
416 cells. *Peer J* 2:1–22 e618
- 417 41. Müntz B, Thier MC, Winnemöller D, Helfen M, Thummer RP, Edenhofer F. 2016. Nanog induces
418 suppression of senescence through downregulation of p27^{KIP1} expression. *Journal of Cell Science*
419 129:912–20
- 420 42. Nishina S., Kohsaka S, Yamaguchi Y, Handa H, Kawakami A, Fujisawa H, Azuma N. 1999. PAX6
421 expression in the developing human eye. *British Journal of Ophthalmology* 83:723–27
- 422 43. Nomura J, Maruyama M, Katano M, Kato H, Zhang J, Masui S, Mizuno Y, Okazaki Ya, Nishimoto M,
423 Okuda A. 2009. Differential requirement for nucleostemin in embryonic stem cell and neural stem
424 cell viability. *Stem Cells* 27:1066–76
- 425 44. Pain D, Chirn GW, Strassel C, Kemp DM. 2005. Multiple retropseudogenes from pluripotent cell-
426 specific gene expression indicates a potential signature for novel gene identification. *Journal of*
427 *Biological Chemistry* 280:6265–68
- 428 45. Pauklin M, Thomasen H, Pester A, Steuhl KP, Meller D. 2011. Expression of pluripotency and
429 multipotency factors in human ocular surface tissues. *Current Eye Research* 36:1086–97
- 430 46. Pesce M, Scholer HR. 2001. Oct-4: gatekeeper in the beginnings of mammalian development. *Stem*
431 *Cells* 19:271–78
- 432 47. Piazzolla D, Palla AR, Pantoja C, Cañamero M, de Castro IP, Ortega S, Gómez-López G, Dominguez
433 O, Megías D, Roncador G, Luque-García JL, Fernandez-Tresguerres B, Fernandez AF, Fraga
434 MF, Rodriguez-Justo M, Manzanares M, Sánchez-Carbayo M, García-Pedrero JM, Rodrigo

- 435 JP, Malumbres M, Serrano M. 2014. Lineage-restricted function of the pluripotency factor NANOG
436 in stratified epithelia. *Nature Communications* 5:4226
- 437 48. Qi X, Li T, Hao J, Hu J, Wang J, Simmons H, Miura S, Mishina Y, Zhao G. 2004. BMP supports
438 self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways.
439 *Proceedings of the National Academy of Sciences* 101:6027–32
- 440 49. Qu Y, Mu G, Wu Y, Dai X, Zhou F, Xu X, Wang Y, Wei F. 2010. Overexpression of DNA
441 methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis. *American*
442 *Journal of Clinical Pathology* 134:826–34
- 443 50. Rad SM, Bamdad T, Sadeghizadeh M, Arefian E, Lotfinia M, Ghanipour M. 2015. Transcription
444 factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for
445 differentiation therapy. *Tumour Biology* 36:2621–29
- 446 51. Rai K, Nadauld LD, Chidester S, Manos EJ, James SR, Karpf AR, Cairns BR, Jones DA. 2006. Zebra
447 fish Dnmt1 and Suv39h1 regulate organ-specific terminal differentiation during development.
448 *Molecular and Cellular Biology* 26:7077–85
- 449 52. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P. 2005. Transcriptional regulation
450 of NANOG by OCT4 and SOX2. *Journal of Biological Chemistry* 280:24731–37
- 451 53. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F. 2007. Human embryonic
452 and neuronal stem cell markers in retinoblastoma. *Molecular Vision* 13:823–32
- 453 54. Sheik MJ, Gaughwin PM, Lim B, Robson P, Lipovich L. 2010. Conserved long noncoding RNAs
454 transcriptionally regulated by Oct4 and Nanog modulate pluripotency in mouse embryonic stem cells.
455 *RNA* 16:324–37
- 456 55. Sun C, Sun L, Jiang K, Gao DM, Kang XN, Wang C, Zhang S, Qin X, Li Y, Liu YK. 2013. NANOG
457 promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through
458 Nodal/Smad3 signaling pathway. *International Journal of Biochemistry & Cell Biology* 45: 1099–108
- 459 56. Tian, L., Kazmierkiewicz, K. L., Bowman, A. S., Li, M., Curcio, C. A. and Stambolian, D. E. 2015.
460 Transcriptome of the human retina, retinal pigmented epithelium and choroid. *Genomics* 105:253-264
- 461 57. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW, Orkin SH. 2006. A protein
462 interaction network for pluripotency of embryonic stem cells. *Nature* 444:364–68
- 463 58. Wang K, Chen Y, Chang EA, Knott JG, Cibelli JB. 2009. Dynamic epigenetic regulation of the Oct4
464 and Nanog regulatory regions during neural differentiation in rhesus nuclear transfer embryonic stem
465 cells. *Cloning And Stem Cells* 11:483–96
- 466 59. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R.
467 2007. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature* 448:318–24
- 468 60. Young RA. 2011. Control of the embryonic stem cell state. *Cell* 144:940–54

469 61. Zhang X, Neganova I, Przyborski S, Yang Ch, Cooke M, Atkinson SP, Anyfantis G, Fenyk S, Keith
470 WN, Hoare SF, Hughes O, Strachan T, Stojkovic M, Hinds PW, Armstrong L, Lako M. 2009. A role
471 for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6
472 and CDC25A. *Journal of Cell Biology* 184:67–82

473

474

475

476 **Figure Legends**

477 **Figure 1.** Electrophoresis of PCR fragments, corresponding to the genes *NANOG* and *PAX6*, on the
478 cDNA template from the human retina (9.5 week of gestation). The length of the nucleotide
479 sequences after amplification cDNA with gene-specific primers were: housekeeping gene RPL19,
480 326 bp (1), *NANOG*, 523 bp (2), *PAX6*, 424 bp (3), M – DNA ladder 1000 bp (Sileks M), marker for
481 the PCR products length; RT(-) – negative control without the template of cDNA; bp – base pair.

482 **Figure 2.** Localization of the *NANOG* mRNA in human eye at early stages of prenatal development:
483 analysis by chromogenic *in situ* hybridization. Hematoxylin an eosin staining of the human eye
484 sections at the 8 to 10.5 weeks of gestation (column A). Hybridization signals with anti-sense RNA
485 probes show the *NANOG* mRNA transcripts in the corneal and lens epithelium, both outer and inner
486 retinal neuroblastic layers (column B) (column B). No hybridization signals with sense RNA probe
487 used as negative control for *NANOG* mRNA (column C) are observed. Abbreviations: PR, peripheral
488 retina; CR, central retina; LEC, lens epithelium cells; CE, corneal epithelium; ON, optic nerve; GCL,
489 ganglion cell layer; INbl, inner neuroblastic layer; ONbl, outer neuroblastic layer; RPE, retinal
490 pigmented epithelium. Scale bars: 500 μ m eye histology (A), 500 μ m *NANOG*, 8–10.5 weeks (B),
491 (C).

492 **Figure 3.** Localization of the *PAX6* mRNA in human eye at the same stages of early prenatal
493 development: analysis by chromogenic *in situ* hybridization. Strong hybridization signals for *PAX6*
494 mRNA are detected in both corneal and lens epithelium, in inner and outer neuroblastic retinal layers.

495 Positive staining is more prominent in peripheral area of retina and is absent in optic nerve (column
496 A) No hybridization signals with sense RNA probe used as negative controls for *PAX6* mRNA
497 (column B) are observed. Abbreviations: PR, peripheral retina; CR, central retina; LEC, lens
498 epithelium cells; CE, corneal epithelium; ON, optic nerve; GCL, ganglion cell layer; INbl, inner
499 neuroblastic layer; ONbl, outer neuroblastic layer; RPE, retinal pigmented epithelium. Scale bars:
500 500 μm *PAX6*, 10.5 weeks (A); 100 μm *PAX6*, 9.5–10 weeks (A), (B).

Figure 1

Electrophoresis of PCR fragments, corresponding to the genes *NANOG* and *PAX6*, on the cDNA template from the human retina (9.5 week of gestation)




Figure 2

Localization of the *NANOG* mRNA in human eye at early stages of prenatal development: analysis by chromogenic *in situ* hybridization




Figure 3

Localization of the *PAX6* mRNA in human eye at the same stages of early prenatal development: analysis by chromogenic *in situ* hybridization

